insulin detemir vs insulin icodec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin detemir · Levemir

Rights held by Novo Nordisk; US product discontinued

Approved in Type 2 Diabetespeptide
Partial signal

NCT00283751 · Phase 3 · completed

The study randomized 583 participants to insulin detemir or insulin glargine, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07) (met)

Result source: NCT00856986

insulin icodec · Awiqli

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT04760626 · Phase 3 · completed

The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.

Next expected readout: October 2027 · NCT07747402 (registry estimate)

Reported efficacy

Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) (met)

Result source: NCT06340854

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin detemirinsulin icodec
HbA1c, change-0.5% vs 0.0%vs Lira 1.8wk 26 · n 160NCT00856986
6 other results
  • -0.5% vs -0.1% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -0.5% vs 0.0% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs -0.7% wk 26 · n 209 · Phase 4 · primary NCT00909480
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
-1.7% vs -1.3%vs Once Daily Basal Insulin Analoguewk 52 · n 542NCT04760626
11 other results
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -0.8% vs -0.6% wk 26 · n 204 · Phase 3 · primary NCT06340854
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805
Body weight, change (kg)-0.1 vs -1.0vs Lira 1.8wk 52 · n 162NCT00856986
8 other results
  • 1.9 vs 5.7 wk 52 · n 234 · Phase 3 · secondary NCT00184600
  • -0.2 vs -0.9 wk 26 · n 162 · Phase 3 · secondary NCT00856986
  • -0.8 vs -1.7 wk 26 · n 103 · Phase 3 · secondary NCT00789191
  • 3.6 vs 6.4 wk 156 · n 234 · Phase 3 · secondary NCT00184600
  • -0.5 vs 1 wk 26 · n 196 · Phase 4 · secondary NCT00909480
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 13 vs 12.6 n 45 · Phase na · secondary NCT01837680
  • 1.2 vs 2.8 Phase 3 · primary NCT00604396
2.3 vs 1.8vs Insulin Glarginewk 52 · n 492NCT04460885
10 other results
  • 2.0 vs 0.6 wk 26 · n 204 · Phase 3 · secondary NCT06340854
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805
HbA1c below 7%—Not posted · NCT00604396—Not posted · NCT05013229
Fasting plasma glucose, change-1.9 vs -0.1vs Lira 1.8wk 52 · n 160NCT00856986
2 other results
  • -2.1 vs -0.4 wk 26 · n 160 · Phase 3 · secondary NCT00856986
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
3-point MACE (% with event)—Not posted · NCT00604396—Not posted · NCT05013229

HbA1c, change

insulin detemir
-0.5% vs 0.0%vs Lira 1.8wk 26 · n 160NCT00856986
6 other results
  • -0.5% vs -0.1% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -0.5% vs 0.0% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs -0.7% wk 26 · n 209 · Phase 4 · primary NCT00909480
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
insulin icodec
-1.7% vs -1.3%vs Once Daily Basal Insulin Analoguewk 52 · n 542NCT04760626
11 other results
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -0.8% vs -0.6% wk 26 · n 204 · Phase 3 · primary NCT06340854
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805

Body weight, change (kg)

insulin detemir
-0.1 vs -1.0vs Lira 1.8wk 52 · n 162NCT00856986
8 other results
  • 1.9 vs 5.7 wk 52 · n 234 · Phase 3 · secondary NCT00184600
  • -0.2 vs -0.9 wk 26 · n 162 · Phase 3 · secondary NCT00856986
  • -0.8 vs -1.7 wk 26 · n 103 · Phase 3 · secondary NCT00789191
  • 3.6 vs 6.4 wk 156 · n 234 · Phase 3 · secondary NCT00184600
  • -0.5 vs 1 wk 26 · n 196 · Phase 4 · secondary NCT00909480
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 13 vs 12.6 n 45 · Phase na · secondary NCT01837680
  • 1.2 vs 2.8 Phase 3 · primary NCT00604396
insulin icodec
2.3 vs 1.8vs Insulin Glarginewk 52 · n 492NCT04460885
10 other results
  • 2.0 vs 0.6 wk 26 · n 204 · Phase 3 · secondary NCT06340854
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805

HbA1c below 7%

insulin detemir
—Not posted · NCT00604396
insulin icodec
—Not posted · NCT05013229

Fasting plasma glucose, change

insulin detemir
-1.9 vs -0.1vs Lira 1.8wk 52 · n 160NCT00856986
2 other results
  • -2.1 vs -0.4 wk 26 · n 160 · Phase 3 · secondary NCT00856986
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
insulin icodec
-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805

3-point MACE (% with event)

insulin detemir
—Not posted · NCT00604396
insulin icodec
—Not posted · NCT05013229
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. insulin detemir: 6 of 6 rows · insulin icodec: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin detemir
Rows use multiple source trials
insulin icodec
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-3.89 mmol/L @ 20wk*a,b,c,d,e
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -70 mg/dL as posted
show 1 more dose
-3.35 mmol/L @ 20wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -60.4 mg/dL as posted
-1.29 mmol/L @ 52wkb,c,d,e
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1% (n=21) @ 20wka,b,c,d,e
NCT01868542 · Phase 4 · registry result, not featured evidence
show 1 more dose
-0.9% (n=23) @ 20wk
NCT01868542 · Phase 4 · registry result, not featured evidence
-1.23% (n=91) @ 52wkb,c,d,e
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
0%f
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
8.7%Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
0%Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
13.9%
NCT01165684 · Phase 4 · registry result, not featured evidence
16.7%
NCT00909480 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
6.9%
NCT00455858 · Phase 4 · registry result, not featured evidence
12.3%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
14.8%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
19.2%
NCT00184600 · Phase 3 · registry result, not featured evidence
12.6%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
0%Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
18.2%Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
15.1%
NCT01837680 · Phase na · registry result, not featured evidence
8.3%g
NCT04760626 · Phase 3
show 14 more results
3.7%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
2%
NCT04795531 · Phase 3
1.1%
NCT04770532 · Phase 3
5.5%
NCT04880850 · Phase 3
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
2%
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
2.4%
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%f
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
—Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
0.5%
NCT01165684 · Phase 4 · registry result, not featured evidence
2.2%
NCT00909480 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
—
NCT00591227 · Phase 4 · registry result, not featured evidence
—
NCT00455858 · Phase 4 · registry result, not featured evidence
1.6%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
2.5%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
—
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
3.8%
NCT00184600 · Phase 3 · registry result, not featured evidence
1.8%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
—Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
—Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
—
NCT01837680 · Phase na · registry result, not featured evidence
—g
NCT04760626 · Phase 3
show 14 more results
—
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT04795531 · Phase 3
—
NCT04770532 · Phase 3
—
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
—
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Serious AEs
10.4%f
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
4.3%Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
0%Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
9.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
3.1%
NCT00909480 · Phase 4 · registry result, not featured evidence
0%
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
5.7%
NCT00455858 · Phase 4 · registry result, not featured evidence
4.1%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
3.3%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
0%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
22.4%
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
33.3%
NCT00184600 · Phase 3 · registry result, not featured evidence
1.9%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
0%Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
0%Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
0%
NCT01837680 · Phase na · registry result, not featured evidence
8.3%g
NCT04760626 · Phase 3
show 14 more results
13%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.8%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.1%
NCT04795531 · Phase 3
8.4%
NCT04770532 · Phase 3
7.6%
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.9%
NCT05823948 · Phase 3 · registry result, not featured evidence
3.7%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
1.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
5.9%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
f
nasopharyngitis 20.2%
nausea 18.4%
diarrhoea 17.8%
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
nasopharyngitis 13%
headache 8.7%
upper respiratory tract infection 4.3%
NCT01868542 · Phase 4 · registry result, not featured evidence
nasopharyngitis 13%
rash 8.7%
upper respiratory tract infection 8.7%
NCT01868542 · Phase 4 · registry result, not featured evidence
nasopharyngitis 8.1%
headache 5.1%
influenza 5.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
nasopharyngitis 10.6%
upper respiratory tract infection 8%
headache 7.5%
NCT00909480 · Phase 4 · registry result, not featured evidence
nasopharyngitis 11.5%
upper respiratory tract infection 5.7%
NCT00455858 · Phase 4 · registry result, not featured evidence
back pain 5.8%
headache 5%
upper respiratory tract infection 5%
NCT00634842 · Phase 4 · registry result, not featured evidence
pain in extremity 3.3%
urinary tract infection 3.3%
anxiety 2.5%
NCT00634842 · Phase 4 · registry result, not featured evidence
nausea 11.1%
diarrhoea 5.6%
hypertension 5.6%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 46.2%
diarrhoea 25.6%
infection 21.4%
NCT00184600 · Phase 3 · registry result, not featured evidence
headache 14.5%
nasopharyngitis 13.2%
back pain 10.5%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
gastrointestinal intolerance 0%
NCT01232946 · Phase na · registry result, not featured evidence
gastrointestinal intolerance 18.2%
NCT01232946 · Phase na · registry result, not featured evidence · combination
biochemical event of hypoglycemia 50.9%
symptomatic hypoglycemia 30.2%
symptomatic nocturnal event 15.1%
NCT01837680 · Phase na · registry result, not featured evidence
g
covid-19 7.9%
NCT04760626 · Phase 3
show 13 more results
covid-19 17.7%
back pain 8.1%
diarrhoea 7.9%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 13.6%
diarrhoea 5.3%
diabetic retinopathy 2.9%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
covid-19 8.2%
diabetic retinopathy 5.1%
influenza 5.1%
NCT04795531 · Phase 3
nasopharyngitis 8.4%
diarrhoea 5.3%
headache 5.3%
NCT04770532 · Phase 3
covid-19 8.6%
diarrhoea 5.2%
diabetic retinopathy 4.1%
NCT04880850 · Phase 3
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.7%
covid-19 9.8%
back pain 7.8%
NCT05823948 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
medical device site haemorrhage 9.3%
headache 5.6%
NCT03922750 · Phase 2 · registry result, not featured evidence
nasopharyngitis 14%
hypertension 6%
influenza 6%
NCT03922750 · Phase 2 · registry result, not featured evidence
headache 11.2%
nasopharyngitis 8%
upper respiratory tract infection 5.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
back pain 9.8%
nasopharyngitis 9.8%
headache 0%
NCT03951805 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.7%
headache 5.9%
back pain 3.9%
NCT03951805 · Phase 2 · registry result, not featured evidence
headache 9.6%
nasopharyngitis 3.8%
back pain 1.9%
NCT03951805 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 20 weeks versus 52 weeks.
  6. fPopulation comparability has not been reviewed for 16 of these studies.
  7. gPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin detemir

Waist Circumference Change -0.78 vs -0.66 Lira 1.8 cm @ 26wk
absolute change · cm
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
Waist Circumference Change -0.83% (n=160) vs -0.83% (n=148) Lira 1.8 @ 52wk
absolute change · percentage points
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7 19.2% (n=193) vs 56.3% (n=183) insulin aspart @ 10wk
absolute value · percentage points
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
45.1% (n=195) vs 65.4% (n=188) insulin aspart @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
55.9% (n=195) vs 63.3% (n=188) insulin aspart @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose 7.1 vs 6.7 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 5 more results
7.1 vs 7 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
7.12 vs 7.01 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
6.22 vs 6.09 IGlar mmol/L @ 26wk
NCT00909480 · Phase 4 · registry result, not featured evidence
6.08 vs 8.52 Sitagliptin mmol/L @ 26wk
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
5.4 vs 5.59 Insulin NPH mmol/L*
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 97.3 mg/dL as posted
Postprandial Glucose Increment 2.3 vs 1.4 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
1.9 vs 1.5 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
1.64 vs 1.28 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Body Weight 89.32 vs 89.8 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
BMI 31.86 vs 32.03 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
HbA1c 7 0 or Less 38% (n=209) vs 53% (n=204) IGlar @ 26wk
responder rate · % of participants
All
NCT00909480 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7 Without Hypoglycemia 32% (n=209) vs 38% (n=204) IGlar @ 26wk
absolute value · percentage points
All
NCT00909480 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6 5 11% (n=209) vs 21% (n=204) IGlar @ 26wk
absolute value · percentage points
All
NCT00909480 · Phase 4 · registry result, not featured evidence
HbA1c Less Than or Equal to 6 5 Without Hypoglycemia 9% (n=209) vs 15% (n=204) IGlar @ 26wk
absolute value · percentage points
All
NCT00909480 · Phase 4 · registry result, not featured evidence
Glucose Variability SD 0.57 vs 0.71 IGlar mmol/L @ 26wk
absolute value · mmol/L
Overall
NCT00909480 · Phase 4 · registry result, not featured evidence

+ 31 further endpoints in the CSV export.

insulin icodec

Time in Range 71.94% (n=439) vs 66.9% (n=440) Insulin Glargine @ 52wk
absolute value · percentage points
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
19.94% (n=202) vs 11.04% (n=198) Insulin Glargine @ 26wk
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
63.13% (n=238) vs 59.5% (n=239) Insulin Degludec @ 26wk
NCT04770532 · Phase 3
Time Below Range 0.27 vs 0.21 Insulin Glargine % of time @ 52wk
absolute value · % of time
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Above Range 26.86 vs 32.27 Insulin Glargine % of time @ 52wk
absolute value · % of time
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
35.52 vs 39.71 Insulin Degludec % of time @ 26wk
NCT04770532 · Phase 3
30.47 vs 31.3 Insulin Glargine % of time @ 26wk
NCT04880850 · Phase 3
Time Above Range -20.54% (n=202) vs -11.19% (n=198) Insulin Glargine @ 26wk
absolute value · percentage points
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 3 0 vs 2 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
0 vs 0 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
0 vs 1 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
7 vs 3 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 53 vs 23 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 41 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
937 vs 935 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 or 3 53 vs 25 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 42 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
944 vs 938 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
DTSQs 4.22 vs 2.96 Insulin Degludec score @ 26wk
absolute change · score
NCT04770532 · Phase 3
Time Below 54 mg/dL 0.34% (n=238) vs 0.22% (n=239) Insulin Degludec @ 26wk
absolute value · percentage points
NCT04770532 · Phase 3
Time in Range 66.88 vs 66.44 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
show 5 more results
65.99 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
72.86 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
76.65 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
82.97 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
80.89 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Time Below 54 mg/dL 0.73 vs 0.61 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
SMBG 7-point -1.69 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT05813912 · Phase 3 · registry result, not featured evidence · combination

+ 4 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin detemir's landscape · insulin icodec's landscape